Gefitinib (Iressa) received FDA approval in 2003 as third-line treatment for metastatic non–small-cell lung cancer (mNSCLC). In phase 3 trials, the tyrosine kinase inhibitor shrunk tumors in only 11% of the efficacy population, but the change in that 11% was dramatic enough to warrant approval.
People don’t adhere to treatment regimens for any number of reasons. IBM’s Watson Health thinks it can put its big-brain cognitive thinking cap on and figure us out, as revealed in the data fingerprints we leave behind when we enter the health care labyrinth.
A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.
Risk-sharing agreements between insurers and drug companies have been used on a limited basis up until now. That’s changing as manufacturers start to offer significant rebates in exchange for preferred status on an insurer’s formulary. For their part, payers want to see quality outcomes and value.
The head of the Institute for Clinical and Economic Review is leading his comparative effectiveness shop into the drug value fray. “We’re kind of holding a mirror up to the system and saying, look, if you want to talk about value … this is what it looks like.”
A Harvard Law School group is among those that have taken action.
Managed care organizations need to work on several fronts if they are to improve patient adherence. Limiting out-of-pocket costs is one place to start.
Sarepta’s eteplirsen functions like an RNA patch so functioning dystrophin gets made. Other drugs like it may be used to treat Ebola and other viral infections.